Ariana Pelosci

A multidisciplinary care approach should be utilized when discussing sexual health with survivors of breast cancer.

For International Women's Day, CancerNetwork highlights impactful oncology research on topics from rising health care costs to innovative treatments.

As a gynecologic oncology surgeon, Mario M. Leitao, MD, FACOG, FACS, highlights how his career has evolved through using robotic surgery, new fertility preservation techniques, and his contributions to the research field.

Median PFS and OS were comparable between age groups when CAR T-cell therapy was given as treatment for patients with relapsed/refractory LBCL.

Scarlett Lin Gomez, MPH, PhD, highlights facts from her research that are impacting cancer disparities and how she is finding ways to improve them.

A team from the University of Munich analyzed HRQOL outcomes in rural/urban patients with bladder cancer and after ADT treatment and postoperative radiotherapy in prostate cancer.

Efficacy results remained consistent with previous reports in the cabozantinib, nivolumab, and ipilimumab arm for patients with advanced renal cell carcinoma.

Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.

Options like acupuncture or cannabis use may be viable to help manage symptoms related to gastrointestinal cancer treatment.

A phase 2 trial found T-DM1 to be a tolerable treatment option for patients with HER2-positive biliary tract adenocarcinoma.

Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.

A pCR rate of 44% was observed when neoadjuvant pembrolizumab was given to patients with dMMR colon cancer.

Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.

Results from the phase 3 LAPIS trial showed pamrevlumab/chemotherapy did not improve survival vs placebo/chemotherapy in locally advanced, unresectable pancreatic cancer.

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Results from the phase 2 FDZL-001 trial showed high OS and PFS rates when camrelizumab plus Nab-POF was used to treat patients with gastric/GEJ cancer.

Results from the CodeBreaK 300 trial helped lead to the approval of sotorasib/panitumumab in KRAS G12C-mutated CRC.

The FDA has approved acalabrutinib in previously untreated MCL based on results from the phase 3 ECHO trial.

Data from CheckMate-67T support the approval of subcutaneous nivolumab in patients with solid tumors across all previously approved nivolumab indications.

Data from the RATIONALE 305 trial support the approval of tislelizumab/chemotherapy in unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma.

Of 18 patients with BRCA-mutated ER+/HER2– breast cancer, 3 had a pathological complete response when treated with niraparib plus dostarlimab.

Phase 2 results showed high undetectable MRD rates with pirtobrutinib, venetoclax, and obinutuzumab for patients with chronic lymphocytic leukemia.

The venetoclax regimen improved CR/CRi rates for patients with acute myeloid leukemia and myelodysplastic syndromes.

Results from the phase 3 ADRIATIC trial led to the approval of durvalumab in limited-stage SCLC.

Zenocutuzumab is now approved for patients with NRG1 fusion-positive NSCLC or pancreatic adenocarcinoma.

Results from the HERIZON-BTC-01 trial led to the approval of zanidatamab for patients with metastatic HER2-positive biliary tract cancer.

Patients with Philadelphia chromosome–positive CML in chronic phase will no longer be required to fast before taking nilotinib tablets.

Nicole Lamanna, MD, discusses addressing a clinically unmet need among patients with CLL who have relapsed on multiple prior lines of therapy.

Patients with newly diagnosed glioblastoma had improved survival when treated with TTFields plus temozolomide and pembrolizumab.

Results from the FELIX trial support the approval of obecabtagene autoleucel in B-cell ALL.